240 related articles for article (PubMed ID: 25231397)
1. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.
Oberthuer A; Juraeva D; Hero B; Volland R; Sterz C; Schmidt R; Faldum A; Kahlert Y; Engesser A; Asgharzadeh S; Seeger R; Ohira M; Nakagawara A; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Grundy RG; Ortmann M; Shao C; Schwab M; Eils R; Simon T; Theissen J; Berthold F; Westermann F; Brors B; Fischer M
Clin Cancer Res; 2015 Apr; 21(8):1904-15. PubMed ID: 25231397
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of gene expression-based classification for neuroblastoma.
Oberthuer A; Hero B; Berthold F; Juraeva D; Faldum A; Kahlert Y; Asgharzadeh S; Seeger R; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Vermeulen J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Weber A; Christiansen H; Grundy RG; Schardt K; Schwab M; Eils R; Warnat P; Kaderali L; Simon T; Decarolis B; Theissen J; Westermann F; Brors B; Fischer M
J Clin Oncol; 2010 Jul; 28(21):3506-15. PubMed ID: 20567016
[TBL] [Abstract][Full Text] [Related]
3. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification.
Oberthuer A; Berthold F; Warnat P; Hero B; Kahlert Y; Spitz R; Ernestus K; König R; Haas S; Eils R; Schwab M; Brors B; Westermann F; Fischer M
J Clin Oncol; 2006 Nov; 24(31):5070-8. PubMed ID: 17075126
[TBL] [Abstract][Full Text] [Related]
4. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
[TBL] [Abstract][Full Text] [Related]
5. Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment.
Rosswog C; Schmidt R; Oberthuer A; Juraeva D; Brors B; Engesser A; Kahlert Y; Volland R; Bartenhagen C; Simon T; Berthold F; Hero B; Faldum A; Fischer M
Neoplasia; 2017 Dec; 19(12):982-990. PubMed ID: 29091799
[TBL] [Abstract][Full Text] [Related]
6. A three-gene expression signature model for risk stratification of patients with neuroblastoma.
Garcia I; Mayol G; Ríos J; Domenech G; Cheung NK; Oberthuer A; Fischer M; Maris JM; Brodeur GM; Hero B; Rodríguez E; Suñol M; Galvan P; de Torres C; Mora J; Lavarino C
Clin Cancer Res; 2012 Apr; 18(7):2012-23. PubMed ID: 22328561
[TBL] [Abstract][Full Text] [Related]
7. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.
De Preter K; Vermeulen J; Brors B; Delattre O; Eggert A; Fischer M; Janoueix-Lerosey I; Lavarino C; Maris JM; Mora J; Nakagawara A; Oberthuer A; Ohira M; Schleiermacher G; Schramm A; Schulte JH; Wang Q; Westermann F; Speleman F; Vandesompele J
Clin Cancer Res; 2010 Mar; 16(5):1532-41. PubMed ID: 20179214
[TBL] [Abstract][Full Text] [Related]
8. An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma.
Formicola D; Petrosino G; Lasorsa VA; Pignataro P; Cimmino F; Vetrella S; Longo L; Tonini GP; Oberthuer A; Iolascon A; Fischer M; Capasso M
J Transl Med; 2016 May; 14(1):142. PubMed ID: 27188717
[TBL] [Abstract][Full Text] [Related]
9. 59-gene prognostic signature sub-stratifies high-risk neuroblastoma patients.
Vermeulen J; De Preter K; Laureys G; Speleman F; Vandesompele J
Lancet Oncol; 2009 Nov; 10(11):1030. PubMed ID: 19880060
[No Abstract] [Full Text] [Related]
10. Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group.
Teshiba R; Kawano S; Wang LL; He L; Naranjo A; London WB; Seeger RC; Gastier-Foster JM; Look AT; Hogarty MD; Cohn SL; Maris JM; Park JR; Shimada H
Pediatr Dev Pathol; 2014; 17(6):441-9. PubMed ID: 25207821
[TBL] [Abstract][Full Text] [Related]
11. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
Schmidt M; Simon T; Hero B; Eschner W; Dietlein M; Sudbrock F; Bongartz R; Berthold F; Schicha H
Nuklearmedizin; 2006; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
[TBL] [Abstract][Full Text] [Related]
12. Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome.
Cornero A; Acquaviva M; Fardin P; Versteeg R; Schramm A; Eva A; Bosco MC; Blengio F; Barzaghi S; Varesio L
BMC Bioinformatics; 2012 Mar; 13 Suppl 4(Suppl 4):S13. PubMed ID: 22536959
[TBL] [Abstract][Full Text] [Related]
13. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples.
De Preter K; Mestdagh P; Vermeulen J; Zeka F; Naranjo A; Bray I; Castel V; Chen C; Drozynska E; Eggert A; Hogarty MD; Izycka-Swieszewska E; London WB; Noguera R; Piqueras M; Bryan K; Schowe B; van Sluis P; Molenaar JJ; Schramm A; Schulte JH; Stallings RL; Versteeg R; Laureys G; Van Roy N; Speleman F; Vandesompele J
Clin Cancer Res; 2011 Dec; 17(24):7684-92. PubMed ID: 22031095
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome.
Fischer M; Oberthuer A; Brors B; Kahlert Y; Skowron M; Voth H; Warnat P; Ernestus K; Hero B; Berthold F
Clin Cancer Res; 2006 Sep; 12(17):5118-28. PubMed ID: 16951229
[TBL] [Abstract][Full Text] [Related]
15. Artificial neural network classifier predicts neuroblastoma patients' outcome.
Cangelosi D; Pelassa S; Morini M; Conte M; Bosco MC; Eva A; Sementa AR; Varesio L
BMC Bioinformatics; 2016 Nov; 17(Suppl 12):347. PubMed ID: 28185577
[TBL] [Abstract][Full Text] [Related]
16. Distillation of the clinical algorithm improves prognosis by multi-task deep learning in high-risk Neuroblastoma.
Maggio V; Chierici M; Jurman G; Furlanello C
PLoS One; 2018; 13(12):e0208924. PubMed ID: 30532223
[TBL] [Abstract][Full Text] [Related]
17. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis.
Agesen TH; Sveen A; Merok MA; Lind GE; Nesbakken A; Skotheim RI; Lothe RA
Gut; 2012 Nov; 61(11):1560-7. PubMed ID: 22213796
[TBL] [Abstract][Full Text] [Related]
18. Expression of two parental imprinted miRNAs improves the risk stratification of neuroblastoma patients.
Gattolliat CH; Le Teuff G; Combaret V; Mussard E; Valteau-Couanet D; Busson P; Bénard J; Douc-Rasy S
Cancer Med; 2014 Aug; 3(4):998-1009. PubMed ID: 24931722
[TBL] [Abstract][Full Text] [Related]
19. MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
DuBois SG; Mody R; Naranjo A; Van Ryn C; Russ D; Oldridge D; Kreissman S; Baker DL; Parisi M; Shulkin BL; Bai H; Diskin SJ; Batra V; Maris JM; Park JR; Matthay KK; Yanik G
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28383813
[TBL] [Abstract][Full Text] [Related]
20. 3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients.
Verly IRN; van Kuilenburg ABP; Abeling NGGM; Goorden SMI; Fiocco M; Vaz FM; van Noesel MM; Zwaan CM; Kaspers GJL; Merks JHM; Caron HN; Tytgat GAM
Eur J Cancer; 2018 Feb; 90():102-110. PubMed ID: 29274926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
